TSX · Biotechnology · CAD
Appili Therapeutics Inc. (APLI.TO) Stock Analysis
Appili Therapeutics Inc. (APLI.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.
Last Updated: October 20, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
APLI.TO Key Statistics
As of Oct 20, 2026Trading
- Open
- CA$0.005
- Previous Close
- CA$0.005
- 52-Week Range
- 0.005–0.03
- Volume
- 10.00K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.14
Valuation
- Market Cap
- CA$661.83K
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 1.83
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.02
Financials (FY)
- Revenue (FY)
- CA$244.18K+143.10%
- Net Income (FY)
- −CA$4.24M
- Shares Outstanding
- 132.37M
- 1-Year Return
- −83.33%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 51.47K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 20, 2026, APLI.TO closed at CA$0.005, −83.33% over 1 year.
Appili Therapeutics Inc. (APLI.TO) has a market capitalization of CA$661.83K.
In fiscal 2025, APLI.TO reported revenue of CA$244.18K.
APLI.TO Stock Return by Calendar Year
Appili Therapeutics Inc. (APLI.TO) return since Jun 2019: what CA$10,000 became
- 1 year
- CA$10,000 CA$1,667
- −83.33%
- 5 years
- CA$10,000 CA$69
- −99.31%
- Since Jun 2019
- CA$10,000 CA$62
- −99.38%
If you had invested CA$10,000 in Appili Therapeutics Inc. (APLI.TO) at the close on June 25, 2019, the earliest close on record here, it would have been worth CA$62 at the close on October 20, 2026: −99.38% in total, −50.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −80.00% |
| 2025 | −28.57% |
| 2024 | +0.00% |
| 2023 | −22.22% |
| 2022 | −60.87% |
| 2021 | −90.57% |
| 2020 | +62.67% |
| 2019 (partial year) | −6.25% |
As of October 20, 2026.
APLI.TO Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | CA$244.18K | −CA$4.24M | −1,736.7% |
| 2024 | CA$100.44K | −CA$2.62M | −2,613.1% |
| 2023 | CA$827.41K | −CA$3.78M | −457.0% |
| 2022 | CA$334.18K | −CA$9.24M | −2,765.9% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | CA$244.18K | — | −CA$3.82M | −CA$4.24M | −1,736.7% |
| 2024 | CA$100.44K | — | −CA$190.84K | −CA$2.62M | −2,613.1% |
| 2023 | CA$827.41K | — | −CA$2.16M | −CA$3.78M | −457.0% |
| 2022 | CA$334.18K | — | −CA$7.78M | −CA$9.24M | −2,765.9% |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
APLI.TO Valuation vs Biotechnology Median
Median of 608 stocks| Metric | APLI.TO | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 1.83 | 13.30 | 0.1x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 20, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B